On the transactional side, Cori routinely advises strategic owners, private equity funds, underwriters and other public and privately-held businesses seeking specialized FDA support in connection with health care and life sciences financing and securities transactions, and domestic and international mergers and acquisitions.  Cori assists companies with regulatory due diligence and deal document drafting and negotiation during these transactions.

Her practice also includes the representation of clients during internal investigations and self-disclosures to government agencies. She also represents large corporations in investigations by the U.S. Food and Drug Administration, U.S. Department of Justice, and other federal and state agencies.

With the passage of the 2018 Federal Farm Bill, Cori has been advising clients about the FDA, USDA, and state law considerations surrounding the use of industrial hemp and other Cannabis derivatives in cosmetics, foods, beverages, and dietary supplements.

Since the start of the COVID-19 public health emergency, Cori has helped companies across various industries with manufacture and distribution of Personal Protective Equipment, cardiac monitors, diagnostic tests, and thermography devices, among others in accordance with FDA Emergency Use Authorizations, enforcement policies, and guidances.